OptiNose (OPTN)

• Market cap: $60.1M
• 1 day: 4.60%
• 5 days: -4.96%
• 1 month: -22.40%
• 3 months: -41.43%
• 6 months: -60.09%
• Year to date: -68.14%
• 1 year: -67.88%
• 5 years: -95.99%
• 10 years: -97.90%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Employees: 132

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 20

12.43% less ownership

Funds ownership: 84.61% [Q2] → 72.18% (-12.43%) [Q3]

22% less funds holding

Funds holding: 83 [Q2] → 65 (-18) [Q3]

43% less capital invested

Capital invested by funds: $128M [Q2] → $72.7M (-$55.6M) [Q3]

75% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 151% upside
• Avg. target: $3 653% upside
• High target: $5 1,155% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler David Amsellem 51% 1-year accuracy 19 / 37 met price target	151% upside $1	Overweight Maintained	13 Nov 2024
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target	1,155% upside $5	Buy Reiterated	13 Nov 2024